Cyclacel Pharmaceuticals (BGMS) Competitors

$1.00 -0.05 (-5.14%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$1.01 +0.02 (+1.91%)

As of 05/15/2026 04:04 PM Eastern

BGMS vs. LPCN, CVKD, QNTM, NCEL, and NAII

Should you buy Cyclacel Pharmaceuticals stock or one of its competitors? MarketBeat compares Cyclacel Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cyclacel Pharmaceuticals include Lipocine (LPCN), Cadrenal Therapeutics (CVKD), Quantum Biopharma (QNTM), NLS Pharmaceutics (NCEL), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry.

How does Cyclacel Pharmaceuticals compare to Lipocine?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Lipocine (NASDAQ:LPCN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for Cyclacel Pharmaceuticals and 2 mentions for Lipocine. Cyclacel Pharmaceuticals' average media sentiment score of 0.96 beat Lipocine's score of 0.43 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cyclacel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	7.33	-$3M	-$4.50	N/A
Lipocine	$1.98M	9.41	-$9.63M	-$1.88	N/A

Lipocine has a consensus target price of $15.00, suggesting a potential upside of 563.72%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Cyclacel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Cyclacel Pharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Cyclacel Pharmaceuticals' return on equity of -58.15% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-58.15%	-48.99%
Lipocine	-571.18%	-66.70%	-59.39%

Cyclacel Pharmaceuticals has a beta of -0.49, suggesting that its stock price is 149% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Summary

Cyclacel Pharmaceuticals beats Lipocine on 9 of the 16 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Cadrenal Therapeutics?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Cyclacel Pharmaceuticals' return on equity of -58.15% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-58.15%	-48.99%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 4 mentions for Cyclacel Pharmaceuticals and 2 mentions for Cadrenal Therapeutics. Cyclacel Pharmaceuticals' average media sentiment score of 0.96 beat Cadrenal Therapeutics' score of 0.87 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Positive
Cadrenal Therapeutics	Positive

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cyclacel Pharmaceuticals has higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	7.33	-$3M	-$4.50	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 157.43%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Cyclacel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cyclacel Pharmaceuticals has a beta of -0.49, suggesting that its stock price is 149% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Summary

Cyclacel Pharmaceuticals beats Cadrenal Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Quantum Biopharma?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclacel Pharmaceuticals' return on equity of -58.15% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-58.15%	-48.99%
Quantum Biopharma	N/A	-941.54%	-224.41%

In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than Quantum Biopharma. MarketBeat recorded 4 mentions for Cyclacel Pharmaceuticals and 1 mentions for Quantum Biopharma. Cyclacel Pharmaceuticals' average media sentiment score of 0.96 beat Quantum Biopharma's score of 0.62 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Positive
Quantum Biopharma	Positive

Cyclacel Pharmaceuticals has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	7.33	-$3M	-$4.50	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cyclacel Pharmaceuticals has a beta of -0.49, suggesting that its share price is 149% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Summary

Cyclacel Pharmaceuticals beats Quantum Biopharma on 10 of the 11 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NLS Pharmaceutics' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Cyclacel Pharmaceuticals	N/A	-58.15%	-48.99%

In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 4 mentions for Cyclacel Pharmaceuticals and 1 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.89 beat Cyclacel Pharmaceuticals' score of 0.96 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Very Positive
Cyclacel Pharmaceuticals	Positive

Cyclacel Pharmaceuticals has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Cyclacel Pharmaceuticals	$750K	7.33	-$3M	-$4.50	N/A

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by company insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NLS Pharmaceutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.49, meaning that its stock price is 149% less volatile than the broader market.

Summary

Cyclacel Pharmaceuticals beats NLS Pharmaceutics on 5 of the 9 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 20.8% of Natural Alternatives International shares are held by company insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclacel Pharmaceuticals has a net margin of 0.00% compared to Natural Alternatives International's net margin of -9.06%. Natural Alternatives International's return on equity of -8.60% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-9.06%	-8.60%	-3.92%
Cyclacel Pharmaceuticals	N/A	-58.15%	-48.99%

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than Natural Alternatives International. MarketBeat recorded 4 mentions for Cyclacel Pharmaceuticals and 2 mentions for Natural Alternatives International. Cyclacel Pharmaceuticals' average media sentiment score of 0.96 beat Natural Alternatives International's score of 0.96 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natural Alternatives International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cyclacel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natural Alternatives International has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.49, meaning that its stock price is 149% less volatile than the broader market.

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.13	-$13.57M	-$2.04	N/A
Cyclacel Pharmaceuticals	$750K	7.33	-$3M	-$4.50	N/A

Summary

Cyclacel Pharmaceuticals beats Natural Alternatives International on 7 of the 13 factors compared between the two stocks.

Get Cyclacel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGMS vs. The Competition

Export

Metric	Cyclacel Pharmaceuticals	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$5.80M	$945.82M	$4.22B	$12.47B
Dividend Yield	N/A	4.84%	5.92%	5.28%
P/E Ratio	-0.22	1.48	22.92	25.24
Price / Sales	7.33	115.93	162.71	78.31
Price / Cash	N/A	20.07	50.14	56.04
Price / Book	0.71	8.22	38.26	6.91
Net Income	-$3M	-$3.77M	$113.55M	$334.11M
7 Day Performance	13.18%	8.41%	2.58%	0.01%
1 Month Performance	-5.14%	62.24%	4.66%	1.17%
1 Year Performance	N/A	116.70%	16.53%	30.68%

Cyclacel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGMS Cyclacel Pharmaceuticals	1.3964 of 5 stars	$1.00 -5.1%	N/A	N/A	$5.80M	$750K	N/A	14	News Coverage Earnings Report Short Interest Decrease
LPCN Lipocine	3.2408 of 5 stars	$2.37 -0.8%	$15.00 +532.9%	-39.4%	$19.03M	$1.98M	N/A	10
CVKD Cadrenal Therapeutics	2.775 of 5 stars	$6.09 +1.2%	$13.00 +113.5%	-66.6%	$18.76M	N/A	N/A	4	Analyst Revision Gap Down
QNTM Quantum Biopharma	0.2434 of 5 stars	$4.88 -2.6%	N/A	-25.6%	$18.64M	N/A	N/A	N/A	Analyst Upgrade
NCEL NLS Pharmaceutics	1.2438 of 5 stars	$3.36 +3.7%	N/A	-80.1%	$17.98M	N/A	N/A	6	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGMS) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cyclacel Pharmaceuticals (BGMS) Competitors

BGMS vs. LPCN, CVKD, QNTM, NCEL, and NAII

How does Cyclacel Pharmaceuticals compare to Lipocine?

Summary

How does Cyclacel Pharmaceuticals compare to Cadrenal Therapeutics?

Summary

How does Cyclacel Pharmaceuticals compare to Quantum Biopharma?

Summary

How does Cyclacel Pharmaceuticals compare to NLS Pharmaceutics?

Summary

How does Cyclacel Pharmaceuticals compare to Natural Alternatives International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGMS vs. The Competition

Cyclacel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cyclacel Pharmaceuticals (BGMS) Competitors

BGMS vs. LPCN, CVKD, QNTM, NCEL, and NAII

How does Cyclacel Pharmaceuticals compare to Lipocine?

Do institutionals & insiders hold more shares of BGMS or LPCN?

Does the media refer more to BGMS or LPCN?

Which has preferable valuation & earnings, BGMS or LPCN?

Do analysts recommend BGMS or LPCN?

Is BGMS or LPCN more profitable?

Which has more volatility and risk, BGMS or LPCN?

Summary

How does Cyclacel Pharmaceuticals compare to Cadrenal Therapeutics?

Is BGMS or CVKD more profitable?

Does the media refer more to BGMS or CVKD?

Do institutionals & insiders hold more shares of BGMS or CVKD?

Which has preferable valuation & earnings, BGMS or CVKD?

Do analysts recommend BGMS or CVKD?

Which has more volatility and risk, BGMS or CVKD?

Summary

How does Cyclacel Pharmaceuticals compare to Quantum Biopharma?

Do analysts recommend BGMS or QNTM?

Is BGMS or QNTM more profitable?

Does the media refer more to BGMS or QNTM?

Which has higher earnings & valuation, BGMS or QNTM?

Do insiders and institutionals hold more shares of BGMS or QNTM?

Which has more risk and volatility, BGMS or QNTM?

Summary

How does Cyclacel Pharmaceuticals compare to NLS Pharmaceutics?

Do analysts prefer NCEL or BGMS?

Is NCEL or BGMS more profitable?

Does the media prefer NCEL or BGMS?

Which has stronger earnings and valuation, NCEL or BGMS?

Do insiders and institutionals hold more shares of NCEL or BGMS?

Which has more risk & volatility, NCEL or BGMS?

Summary

How does Cyclacel Pharmaceuticals compare to Natural Alternatives International?

Do insiders and institutionals hold more shares of NAII or BGMS?

Do analysts prefer NAII or BGMS?

Is NAII or BGMS more profitable?

Does the media prefer NAII or BGMS?

Which has more risk & volatility, NAII or BGMS?

Which has stronger earnings and valuation, NAII or BGMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGMS vs. The Competition

Cyclacel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools